Pancreatic Cancer Research

ResearcherKansai Medical UniversityNo recent work listed

Hironori Ryota

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5694-7434; OpenAlex author ID A5087384413. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2016: 4 papers · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 3 papers

Papers 11

  1. Nutritional impact of active hexose-correlated compound for patients with resectable or borderline-resectable pancreatic cancer treated with neoadjuvant therap… Co-author DOI 10.1007/s00595-021-02308-3↗
  2. Does direct invasion of peripancreatic lymph nodes impact survival in patients with pancreatic ductal adenocarcinoma? A retrospective dual-center study. Co-author DOI 10.1016/j.pan.2021.03.008↗
  3. Clinicopathological characteristics of pancreatic ductal adenocarcinoma with invasive micropapillary carcinoma component with emphasis on the usefulness of PKC… Co-author DOI 10.3892/ol.2021.12786↗
  4. Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers12061428↗
  5. Adipophilin expression is an indicator of poor prognosis in patients with pancreatic ductal adenocarcinoma: An immunohistochemical analysis. Co-author DOI 10.1016/j.pan.2019.03.001↗
  6. Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy. Co-author DOI 10.1007/s00595-016-1358-9↗
  7. PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8+ tumor-infiltrating lymphocytes: highly sensitive de… Co-author DOI 10.1007/s10147-017-1112-3↗
  8. Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreatoduodenectomy in patients with pancreati… Co-author DOI 10.1002/jhbp.318↗
  9. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic … Co-author DOI 10.1007/s00280-015-2928-z↗
  10. Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarc… Co-author DOI 10.1080/01635581.2016.1134597↗
  11. A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12957-016-0767-y↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. So Yamaki · 11 shared papers, 2016–2021 · strength 0.91
  2. Sohei Satoi · 10 shared papers, 2016–2021 · strength 0.82
  3. Tomohisa Yamamoto · 10 shared papers, 2016–2021 · strength 0.82
  4. Satoshi Hirooka · 9 shared papers, 2016–2021 · strength 0.71
  5. Hiroaki Yanagimoto · 9 shared papers, 2016–2021 · strength 0.67
  6. Masanori Kon · 6 shared papers, 2016–2017 · strength 0.35
  7. Mitsugu Sekimoto · 3 shared papers, 2020–2021 · strength 0.35
  8. Tatsuma Sakaguchi · 2 shared papers, 2021 · strength 0.24
  9. Daisuke Hashimoto · 2 shared papers, 2021 · strength 0.24
  10. Masayuki Sho · 3 shared papers, 2016–2021 · strength 0.21
  11. Takahiro Akahori · 3 shared papers, 2016–2021 · strength 0.21
  12. Minako Nagai · 3 shared papers, 2016–2021 · strength 0.21
  13. Kenji Nakagawa · 1 shared paper, 2021 · strength 0.11
  14. Taichi Terai · 1 shared paper, 2021 · strength 0.11
  15. Tadataka Takagi · 1 shared paper, 2021 · strength 0.11
  16. Yoshiyuki Nakajima · 2 shared papers, 2016 · strength 0.10
  17. Satoshi Nishiwada · 2 shared papers, 2016 · strength 0.10
  18. Naoya Ikeda · 2 shared papers, 2016 · strength 0.10
  19. Shoichi Kinoshita · 2 shared papers, 2016 · strength 0.10
  20. Yuki Hashimoto · 1 shared paper, 2019 · strength 0.09
  21. Singh Sapam Opendro · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.